Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients


Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Nicholas J. Short, MD, of the University of Texas MD Anderson Cancer Center, explained what’s coming next for the field of acute lymphoblastic leukemia (ALL) at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.


It’s important that we continue to optimize ALL regimens. And with all regimens, there is a risk of toxicity with intensive chemotherapy and with long durations of chemotherapy. It’s relatively rare in a very fit population, but there are still patients who get significant cytopenias, have major infections, or even die in remission because of the need for repetitive [therapy] cycles, at least with our current paradigms of chemotherapy. If there’s anything that we can do to identify patients who don’t need to continue with 2 to 3 years of maintenance therapy, that would be clinically important.

A big question in the field of ALL in general is, “which patients need transplant?” Obviously, transplant comes with significant morbidity and potential for mortality. If we can identify patients who don’t need a transplant in first remission, that would be important for improving long-term outcomes for these patients.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
Related Content